How does the Animals (Scientific Procedures) Act 1986 influence AAV dosing protocols?

The Animals (Scientific Procedures) Act 1986 (ASPA) mandates a rigorous ethical review and licensing process for all in vivo studies in the UK. For AAV dosing, this requires protocols to be meticulously designed to minimize pain, suffering, distress, or lasting harm. Every aspect, from dose volume and administration route to the frequency of monitoring and the definition of humane endpoints, must be scientifically justified and refined to the highest possible standard.

What are the primary welfare endpoints monitored during neonatal AAV administration?

In neonatal studies, key welfare endpoints include daily body weight measurements, assessment of hydration and suckling reflexes, body temperature, and general activity levels. Any failure to thrive, signs of distress, or observable adverse reactions to the vector are recorded and managed according to predefined intervention criteria, ensuring adherence to the study’s ethical license and humane endpoints.

How do you mitigate immunogenicity when dosing AAV vectors in immunocompetent models?

Mitigating immunogenicity involves several strategies, starting with AAV serotype selection to reduce pre-existing neutralising antibodies. Protocol design may also incorporate transient immunosuppressive regimens, though this is carefully balanced against potential confounding effects on study outcomes. The primary approach remains careful dose optimisation to use the lowest effective vector genome concentration that achieves the desired therapeutic effect, thereby lowering the overall antigenic load.

What determines the choice between single vs. dual AAV vector systems for in vivo studies?

The choice is dictated by the size of the genetic payload. Standard AAV vectors have a packaging capacity of approximately 4.7 kilobases. For larger transgenes, such as the components required for CRISPR-Cas9 gene editing systems, a dual-vector system is often necessary. This approach splits the payload into two separate AAV vectors that are co-administered, requiring careful optimisation of the dosing ratio to ensure efficient co-transduction of target cells.

Refining in vivo dosing procedures for adeno-associated virus (AAV) vectors is fundamental to generating reproducible, high-integrity data for regulatory submissions. Within the United Kingdom, this process is governed by the Animals (Scientific Procedures) Act 1986, which places a legal and ethical emphasis on protocol refinement. For gene therapy developers, optimising AAV administration in murine models directly impacts data quality, adherence to the 3Rs principles, and the ability to meet an 18-24 month IND timeline.

Technical Considerations for Protocol Design

Developing a robust AAV dosing protocol requires a multi-factorial approach. Each parameter is optimised based on the vector, target tissue, and scientific objective.

• Vector Serotype & Promoter: Selection is based on target cell tropism and desired expression kinetics.

• Dose Volume & Concentration: Calculated to achieve therapeutic effect while minimising potential toxicity and staying within physiological limits for the administration route.

• Route of Administration: Chosen to maximise vector delivery to the target organ and limit non-target tissue biodistribution.

• Humane Endpoints: Clearly defined, protocol-specific clinical signs that trigger intervention or study removal to prevent unnecessary distress.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

This deep expertise in AAV vector biology, transitioned from leading academic cores, informs our approach to in vivo study design. Our track record includes a 100% IND success rate for programs we have supported since 2019, with the Franklin Biolabs brand itself having launched in 2024.